AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed...

|About: Baxter International Inc (BAX)|By:, SA News Editor
AAIC 2012: Baxter's (BAX +1%) Gammagard immune system therapy for Alzheimer's disease performed well in Phase 2 trials, with 4 patients who received the most effective dose experiencing a stabilization over 3 years. It's all very small scale, and the proof will come early next year with the results of a larger Phase 3 study, but it's still really encouraging.